Excreted Unchanged %
70-97
Half-Life (Normalesrd) Hours
19-23/48-60
Plasma Protein Binding %
13-17
Volume Of Distribution L/Kg
0.6-0.8
Dose For Normal Renal Function
200 mg q12h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
50% [A]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
25% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Dose for normal renal function after dialysis, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: Dose for GFR 10-50, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [B]
References
Gisclon LG, Riffits JM, Sica DA, et al. The pharmacokinetics of topiramate in subjects with renal impairment as compared to matched subjects with normal renal function. Pharm Res. 1993; 10: S397. [PMID unavailable] / Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet. 1996; 31: 29-46.[PMID: 8827398] / Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. 1996; 37: 774-80. [PMID: 8764818]